VERA | Ticker Profile - Titan Protect

VERA

Vera Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$32.29

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-9.56

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-71.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$82.00

+154% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

https://veratx.com

Country: United States Employees: 339 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.326

Positive but modest risk-adjusted returns

Kelly Fraction

0.0312

Modest edge detected — smaller position warranted

Calmar Ratio

-0.028

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-1.7%

Historical annualised return based on price data

Max Drawdown

-62.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

101

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.95

Less volatile than the market — more defensive

52W High

$56.05

42% below the year high

52W Low

$18.76

72% above the year low

Avg Volume

1,171,837

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.54

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

15.39

Heavy leverage — higher financial risk if revenues decline

Current Ratio

13.64

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

13.30

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-179,415,120

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-368,952,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$110.00

Target Median

$82.00

Target Low

$35.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go